UNSPSC 51112708: Picoplatin

This classification denotes a platinum compound with the molecular structure C6H7N.2CL.PT.H3N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, B5TAN0L720 chemically known as platinum, amminedichloro(2-methylpyridine)-, (sp-4-3)-, but more commonly known as picoplatin, which bears US NIH Compound Identifier 177358. European Medicines Agency schedules Picoplatin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB29605.

The term PICOPLATIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 17, no. 2, 2003, list 49). Picoplatin bears US NLM identifiers UMLS ID C0671135 and NCI Concept Code C48416. Most nations, for tariff and trade purposes, schedule picoplatin under HS 28439000 and SITC 52432. SMILES: CC1CCCCN1.N.[CL-].[CL-].[PT+2].

UNSPSC 51112708 Picoplatin is a Commodity code covering a platinum-based chemotherapy agent used in cancer treatment protocols. State and local governments procure this pharmaceutical through health departments, hospital systems, and public health agencies as part of their oncology and cancer care programs. The code encompasses procurement of the active pharmaceutical ingredient and finished pharmaceutical preparations for intravenous administration in clinical settings, typically via standing orders, blanket purchase agreements, or cooperative purchasing vehicles managed at the state health-system or regional level.

The source provides no recent state or local contract opportunities tagged to this code. Without posted solicitations or awarded contracts in the available dataset, the current market activity under UNSPSC 51112708 cannot be characterized. Verify current procurement activity directly with state health departments, state university hospital systems, and regional cancer centers in your target markets before committing business development resources to this code.